SynthesisInternational ophthalmology2025
Visual field outcomes after cataract surgery with or without microinvasive glaucoma surgery in open-angle glaucoma: a systematic review and meta-analysis of RCTs reporting visual field results.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Should Schlemm Canal-Based MIGS Be Combined with Cataract Surgery in Patients Receiving Topical Glaucoma Therapy? A Cataract Surgeon-Oriented Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the benefits of combining microinvasive glaucoma surgery (MIGS) with cataract surgery (CS) for visual field (VF) preservation in patients with primary open-angle glaucoma (POAG) and coexisting cataracts.
methodsA systematic review and meta-analysis were conducted on randomised controlled trials (RCTs) comparing MIGS + CS to CS alone in POAG patients with cataracts that specifically reported visual field outcomes. Studies included were required to report VF outcomes with a follow-up of at least 12 months. Subanalysis focused on studies with 24-month follow-up durations, and consistent device used.
resultsThree RCTs encompassing 857 eyes were included, with 523 eyes in the MIGS + CS group and 334 in the CS group. MIGS + CS was associated with a statistically significant reduced rate of VF deterioration in Mean Deviation (MD) at the 24-month follow-up compared to CS alone (SMD 0.29; p = 0.007), and a significant difference between groups in the rate of VF progression (MD 0.23 decibels (dB)/year; p = 0.00001). However, there was no difference in IOP reduction (MD -0.46 mmHg; p = 0.40). The MIGS + CS group showed a significant reduction in medication use (MD -0.36 medications; p < 0.00001).
conclusionAmong the MIGS devices studied (iStent and Hydrus), combining them with cataract surgery provided VF benefits in terms of rate of deterioration and decline, and reduced medication dependence. Standardised follow-up and reporting practices are essential for evaluating MIGS's role in glaucoma management.
Indexed as
Identifiers
40437308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.